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Abstract 
Cancer represents one of the largest public health concerns in the world. Current treatment methods 
for cancer – namely, chemotherapy – possess serious limitations, most notably the nonspecific 
biodistribution of the cytotoxic drugs, which leads to diminished drug efficacy and undesirable 
side effects. However, nanomedicines have recently demonstrated great promise in improving the 
target specificity of chemotherapeutic drugs and thus drug efficacy. Nanomedicines can be 
designed with ideal properties for drug delivery, and they are able to preferentially accumulate in 
the diseased site by the enhanced permeability and retention (EPR) effect. However, there are still 
numerous biological barriers to drug delivery that need to be considered when designing these 
nanomedicines. In order to overcome these barriers, the nanomedicines or nanoparticles must be 
rationally designed. By tuning such properties as size, shape, elasticity, hydrophobicity, and 
surface charge – these nanoparticles can be passively targeted to the diseased site, and even into 
the cancerous cells. However, it is also beneficial to actively target tumors by functionalizing the 
particles with target ligands that can preferentially bind to unique or overexpressed receptors or 
molecules at the tumor site, thereby improving target specificity, as well as facilitating uptake of 
the nanoparticles by the cell. In the original work of this thesis, the use of pH-sensitive nanogels 
as drug delivery agents for ovarian cancer was investigated. There were three aims of this 
investigation: (1) to elucidate the mechanism of internalization in order to determine if endosomal 
acidification could be leveraged to facilitate cytosolic delivery of the drug payload, (2) to evaluate 
the effect of stealth coating (PEG) surface density on cellular uptake, (3) and – expecting that the 
presence of a stealth coating would impede uptake – to design a stimuli responsive peptide linker 
that would facilitate the shedding of the stealth coating in the presence of a key enzyme that is 
over expressed in cancer cells – thereby improving uptake. Ultimately, it was determined that the 
nanogels were internalized via a clathrin-mediated endocytosis process. As a result, these nanogels 
can, in fact, leverage endosomal acidification to induce nanoparticle swelling, endosomal rupture, 
and cytosolic delivery. Additionally, particles with no PEG conjugated to the surface exhibited 
about 90% uptake, but this uptake diminished to about 10% or lower for particles with a PEG 
content of 10 mol% or higher, showing that the increase in PEG content severely hindered cellular 
uptake. However, nanoparticles with the enzyme degradable crosslinker that functionalized the 
PEG to the particle surfaces were successfully synthesized, and it was seen that – in the presence 
of the enzyme – shedding of the stealth coating was, in fact, observed, and uptake levels returned 
to those of the particles without PEG coatings. Therefore, it can be concluded that nanogels were 
rationally designed and successfully synthesized that possessed a multitude of functionalities, each 
of which contributed to the capacity of the nanogels to delivery drugs to a specific target with a 
controlled release of the drug payload. 
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Chapter One: Literature Review 
Introduction 
While the cancer incidence and death rates appear to be declining for both men and women, 
it remains a major public health problem world-wide. According to American Cancer Society 
estimates in 2018, there were about 1.7 million new cancer cases with an expected death toll of 
over 600,000 Americans alone – making cancer the second most common cause of death in the 
US, exceeded only by heart disease [1]. Globally, about 1 in 6 deaths are due to cancer, with an 
estimated 9.6 million deaths in 2018. Additionally, the economic impact of cancer is significant, 
with a total annual cost of nearly $1.16 trillion in 2010 [2]. 
The current standard of care for cancer patients is generally some combination of surgery, 
radiation therapy, immunotherapy, and chemotherapy. Chemotherapy involves the application of 
chemicals or drugs to kill cancer cells in a systemic fashion. While there are numerous types of 
anticancer drugs, there are common ones that are classified by their mechanism of action, including 
the following: a) alkylating agents which damage DNA – like Cisplatin and Carboplatin; b) anti-
metabolites that replace the normal building blocks of RNA and DNA – like Methotrexate; c) 
antibiotics that interfere with the enzymes involved in DNA replication – like Doxorubicin; d) 
topoisomerase inhibitors that inhibit either topoisomerase I or II (like Topotecan or Etoposide, 
respectively), which are the enzymes involved in unwinding DNA during replication and 
transcription; e) mitotic inhibitors that inhibit mitosis and cell division – like Paclitaxel; and f) 
corticosteroids, like Prednisone, which are used for the treatment of cancer and to relieve the side 
effects from other drugs [3]–[5]. However, for each of the aforementioned drugs, there are 
numerous limitations, drawbacks, and side effects. One of the primary issues with current 
chemotherapeutics is the nonspecific cell and tissue biodistribution, resulting in diminished drug 
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efficacy and undesirable side effects. Additionally, some administered drugs are rapidly 
metabolized or excreted from the body prior to achieving their intended effect. Therefore, a need 
arises for a delivery agent that can improve the target specificity and half-life of the drugs [6]–[9]. 
Recently, nanomedicines have received attention for their potential to be designed in order 
to overcome the limitations associated with conventional drugs [10].  These nanomedicines or 
nanocarriers have numerous notable advantages to the current chemotherapeutic agents. They 
possess unique properties such as their nanoscale size, high surface-to-volume ratio, and favorable 
physicochemical characteristics; they can affect the pharmacokinetic and pharmacodynamic 
profiles of drugs to improve the drugs’ therapeutic index; and they can improve in vivo stability 
and blood circulation time [6]–[9], [11]. Additionally, nanomedicines can be rationally designed 
with passive or active targeting functionalities, in addition to stimuli-responsive properties that 
allow for the controlled release of the drug cargo [11]. Furthermore, Due to tumors’ aberrant 
vasculature, cancerous tissues often exhibit a phenomenon called the enhanced permeability and 
retention effect, allowing for the preferential accumulation of macromolecules and nanomaterials 
at tumor sites [6]–[9]. Currently, myriad different compound types of nanomedicines are being 
studied, including but not limited to albumin-bound nanoparticles, pegylated-liposomes, natural 
and synthetic polymer-drug conjugates, and various inorganics [11], [12]. While these 
nanomedicines exhibit great potential for overcoming the various biological barriers imposed 
against drug delivery, there are still numerous challenges that need to be met. In order to be an 
effective drug carrier, the nanomedicine must be viable through various stages of circulation, 
extravasation, accumulation, distribution, endocytosis, endosomal escape, intracellular 
localization, and ultimately action. Unfortunately, current nanomedicines tend to prove successful 
in one, maybe two of those drug-life stages. Therefore, careful consideration must be made when 
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rationally designing future carriers that have the potential of successful delivery, distribution, and 
accumulation [13].  This thesis describes each stage of a nanomedicine’s journey through the body 
and the current research being performed to improve the drug delivery capabilities of nanocarriers. 
Furthermore, in this thesis after the literature review, original work from the Peppas lab concerning 
the design of a stimuli-responsive nanogel with improved cellular delivery and uptake capabilities 
is presented. 
Hallmarks of Cancer and Tumor Biology 
In order to understand the goal of rational nanocarrier design, it is first important to 
understand how tumors – the targets of the carriers – behave and what their characteristics are. 
Various physicochemical parameters of the nanoparticles affect the nanoparticle-tumor interaction 
which is crucial for their delivery, uptake, and efficacy. Furthermore, the nanoparticles could be 
designed to exploit the differences between normal and malignant cells at the cellular and 
molecular level. Therefore, tumor physiology must be understood in order to better tune the 
properties of the nanocarriers such that they may overcome the biological barriers. 
Tumors develop in a number of ways. Generally, homeostasis occurs within the body to 
maintain healthy, normal tissue by providing a stable tissue structure and by carefully controlling 
the proliferation and death of cells. However, through the exposure of the body to carcinogens, 
mutagens, toxins, radiation, and other infections, tissue homeostasis can be perturbed leading to 
cellular mutations and tumorigenesis. Furthermore, if the body does not prevent further 
development of the initial tumor, it may grow uncontrollable, proliferate, and eventually 
metastasize [14]. 
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Cancer metastasis is a complex multistage process in which cancer cells separate from the 
initial primary tumor, survive in the circulation of the vascular or lymphatic system, and then seed 
at distant sites where they may proliferate to form new tumors. In order for metastasis to occur, 
the cancer cells must possess specific markers, proteins, and factors that can facilitate their 
invasion of surrounding stroma, their intravasation, and ultimately their extravasation [15]. 
First, the metastatic cascade is dependent on the loss of adhesion between cells, allowing 
for the dissociation of the cell from the primary tumor. The cell-to-cell adhesion complex possesses 
a composition of cell adhesion molecules (CAMs), tight junctions, adherens junctions, gap 
junctions, desmosomes, and integrins. Therefore, these junctions and binding agents must be 
disrupted by the cancer cells through various cell pathways of upregulation or downregulation. For 
instance, HGF/SF – a hepatocyte growth factor – is a cytokine secreted by stromal cells that is 
known to modulate the expression of tight junction molecules in various human breast cancer cell 
lines. HGF disrupts the function of the tight junctions in the human breast cancer cells by changing 
expression of several tight junction molecules at both the mRNA and protein levels [16]. 
Furthermore, HGF was shown not only to damage the tight junctions, but also to decrease trans-
epithelial resistance, allowing for improved paracellular permeability, which is critical to cancer 
metastasis [17]. 
In order to invade surrounding stromal tissues and intravasate the circulatory system, the 
cancer cells must exhibit improved motility. There are numerous compounds that have been 
discovered that are associated with a process similar to epithelial mesenchymal transition (EMT), 
wherein cell signaling processes lead to a loss of epithelial character and a gain of mesenchymal 
character, which has improved migration abilities [15]. One such class of compounds are matrix 
metalloproteinases (MMPs) which are proteases that cleave cell-adhesion molecules and 
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extracellular matrix proteins – like E-cadherin – disrupting the cell junctions, loosening cell 
contacts, and allowing the cancer cells to migrate and invade surrounding tissue and vasculature 
[15], [18], [19]. 
In order to travel to new parts of the body, cancer cells must reach and exploit the body’s 
vasculature and lymphatic systems. Cancerous cells exhibit increased expression of proangiogenic 
factors which leads to neovascularization and the development of tumor microvessels. This tumor 
vasculature – distinct from healthy tissue – tends to possess structural and physiological 
abnormalities such as arterio-venous shunts, blind ends, incomplete endothelial linings and 
basement membranes, and a general lack of smooth muscle or enervation  [20]. Consequently, the 
blood flow in these microenvironments is tortuous, highly irregular, and leakier than that of normal 
tissues [21]–[23]. Similar to the angiogenesis process, lymphangiogenesis is an important process 
that is associated with cancer progression and metastasis, as well. Cancer cells tend to overproduce 
a variety of factors – such as vascular endothelial growth factors (VEGFs) – in order to stimulate 
both blood and lymphatic vessel growth, which are then exploited by metastasizing cells to 
circulate within the body [24]. Although cancer cells produce their own vasculature, they also 
exhibit such rapid, unrestrained growth that it often forces the cells to develop beyond the distance 
to which oxygen could diffuse. Therefore, the oxygenation of cancer cells becomes highly 
heterogeneous, leading to tumor hypoxia and even necrotic tissues which can prove harmful to 
surrounding tissues [25]. 
As described, in order to metastasize throughout the body and develop secondary tumors, 
cancer metastases must break from their cell-cell and cell-matrix interactions, invade surrounding 
tissues, undergo intravasation, survive in circulation, and finally extravasate into a final location 
and proliferate. Some kind of cell pathway or expression must be altered to facilitate each of these 
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steps which provides certain targets for therapy. However, not all of the potentially targetable 
markers for cancer have been identified. Additionally, metastasis in general poses a large problem 
for cancer treatment. Upon metastasizing, the cancer cells migrate from their primary cancer site 
to secondary cancer sites, potentially with new properties, which demands the treatment of 
multiple types of cancers. Additionally, some metastatic events cannot be detected, and certain 
cancers tend to be asymptomatic, leading to a lack of diagnosis, which allows the metastasized 
cancer to progress uninhibited [26]. Furthermore, tumors, during or after treatment, can become 
drug resistant by a number of different mechanisms. In most cases, the resistance is inherent to the 
cancer, but acquired resistance is also common. Some cancers express an energy-dependent drug 
efflux pump – known as P-glycoprotein (P-gp), a member of the ATP binding cassette family of 
transporters – which detects the presence of the anticancer drugs and ejects them [27]. 
Additionally, there are other forms of drug resistance such as the development of insensitivity to 
drug-induced apoptosis and the induction of various drug-detoxifying mechanisms [28]. Clearly, 
there are numerous limitations with current chemotherapeutic approaches and a wealth of 
metastatic cancer related issues that need to be addressed. 
Barriers to Delivery 
While designing nanoparticles as drug delivery agents for chemotherapy, it is important to 
consider the various barriers posed against delivery. The nanoparticles need to do the following 
things for successful delivery: remain stable in circulation without releasing the drug prematurely, 
accumulate in the tumor efficiently, and release the drug locally in the tumor tissue or inside the 
tumor cells. For each of these steps of delivery there could be one or more distinct barriers to 
overcome. 
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The drugs must first overcome the first pass effect, wherein the concentration of the drug 
is reduced due to metabolism in the liver or the gut prior to its reaching the systemic circulation – 
severely affecting the bioavailability of the drug [29]. This first pass effect can be avoided using 
alternative routes of drug administration that allow the drugs to be put directly into the systemic 
circulation, such as intravenous administration. However, the drug can still be removed from the 
system due to rapid renal clearance in the kidneys if the hydrodynamic diameter of the drug is 
below a certain threshold. 
After being processed and entering the circulatory system, the drugs must avoid clearance 
from the body by means of opsonization and presentation to the macrophages of the mononuclear 
phagocytic system (MPS), otherwise referred to as the reticuloendothelial system (RES). During 
circulation in the blood, opsonins and other blood serum proteins bind to foreign particles by means 
of various attractive forces, such as van der Walls, electrostatic, ionic, hydrophobic and 
hydrophilic and others – forming a ‘protein corona’ [30]. After opsonization, phagocytosis can 
occur, leading to the removal of the drugs from the system. By binding to the drugs or 
nanoparticles, the opsonins transition from an inactive to an active conformation that can then bind 
to specialized cell surface receptors on the phagocytes in order to induce phagocytosis [31]. One 
popular means of shielding the nanoparticles and drugs from opsonization, and thus the 
introduction of the particles to the MPS, is through PEGylation. By decorating the particle surface 
with charge-neutral, hydrophilic PEG through covalent grafting, entrapment, or adsorption, the 
charge of the surface is altered, and the shielding groups can then block the electrostatic and 
hydrophobic interactions that facilitate opsonization. Therefore, PEGylation of nanoparticles is a 
useful means of improving the circulation time of drugs in the bloodstream [31]. 
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After circulation, the nanocarriers that remain must effectively extravasate through the 
vascular endothelial layer in order to ultimately reach the tumor tissue itself. However, as 
previously described, a tumor’s physiology tends to be abnormal, which makes the nanoparticles’ 
hemodynamics a concern during the designing process. While abnormalities can lead to certain 
benefits, such as providing gaps in the endothelial lining through which particles can extravasate 
and accumulate by the EPR effect, the tumor vasculature can also pose certain barriers to drug 
delivery. For instance, as described, a tumor’s abnormal growth rate and behavior can lead to 
vasculature with chaotic connectivity, heterogenous blood flow, and a high interstitial pressure. 
These spatial and temporal heterogeneities in blood supply result in a tortuous pathway for 
diffusion of the nanocarriers into the tumor microenvironment. As such, the spatial distribution of 
therapeutic agents in tumors is not uniform; uptake is decreased; and successful delivery is difficult 
[32]. 
Once within the tumor microenvironment, the nanoparticles must then cross the 
extracellular-matrix (ECM), which provides structural integrity to the tissue through a cross-linked 
network of collagen, elastin fibers, proteoglycans, hyaluronic acid, and other structural proteins 
and components. Depending on the complexity of the matrix, it could potentially increase the 
resistance to the diffusion of the nanoparticles to the cancerous cells – thereby preventing the 
therapeutics from having their intended effect [33]. 
The final barrier to delivery is the cell membrane itself. In order for the therapeutic to 
successfully bring about cell death, it more often than not needs to diffuse across the cell membrane 
and be internalized. However, endocytosis of the nanoparticle is mediated by a variety of different 
cell pathways and can be affected by numerous properties of the nanoparticles, such as surface 
charge, size, hydrophobicity or hydrophilicity, shape, flexibility, coating, and ligand density – as 
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each of these properties will affect the nanoparticles’ interactions with the cell membrane and its 
receptors. Additionally, in crossing the membrane, the nanoparticles become encapsulated in an 
endosomal vesicle, and the intracellular sites or organelle to which the cargo is trafficked is pre-
determined, signal-dependent, and critical to effective therapy [34]. The nanoparticles, thus, must 
escape from the endosome or the lysosome to which the endosome fused in order to be dispelled 
into the cytoplasm and cause their cytotoxic effects. There are numerous classes of nanoparticles 
that achieve this effect in various ways. For instance, some materials like fusogenic lipids undergo 
phase transitions due to the acidic pH environment of the endosomes or lysosomes, which allows 
them to then fuse with the membrane and enter the cytoplasm [35]. Even after escaping into the 
cytoplasm, though, only a partial fraction of the original drug dosage can affect cell death because 
some of the drugs are recycled back out of the cells. Some tumors implore drug efflux transporters 
to prevent compounds that are dangerous to the cells from exerting their intended effect [36]. 
Clearly, there are numerous barriers to overcome in order for nanoparticle drug carriers to prove 
effective in intracellular delivery. 
Mechanisms of Internalization 
As previously mentioned, cells possess multiple pathways through which materials like 
nanoparticles can be internalized, namely pinocytosis – which includes macropinocytosis, clathrin-
mediated endocytosis, caveolin-mediated endocytosis and clathrin- and caveolin-independent 
endocytosis – and phagocytosis, which involves the engulfing of large particles. It is crucial to 
understand the mechanism by which nanoparticles used for drug delivery are internalized in order 
to better tailor their properties for improved uptake. In this section, each mechanism and the factors 
that determine its use will be described. 
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Both phagocytosis and macropinocytosis are actin-dependent mechanisms that result in the 
internalization of particles or materials in the micrometer size range [37]. During phagocytosis, a 
phagocyte, such as a macrophage, will interact with the particle via a receptor and trigger uptake 
by the formation of a phagosome [38]. Macropinocytosis similarly involves the engulfment of 
particles in addition to a large amount of extracellular fluid through to formation of membrane 
protrusions that ultimately recombine with the cell membrane forming a macropinosome [37]. 
Clathrin-mediated endocytosis – also referred to as receptor-mediated endocytosis – is a 
cellular uptake mechanism during which the binding of a ligand on the particle to the membrane 
surface receptors triggers the formation of clathrin-coated endocytotic vesicles approximately 100 
nm in diameter [39]. The clathrin assembly induces the vesicle formation initiation as well as the 
vesicle necking and pinching after successfully wrapping of the membrane around the material 
[37]. Release of the vesicle from the plasma membrane occurs due to the activity of a GTPase 
called Dynamin, and these released vesicles either become recycling endosomes or early 
endosomes that ultimately differentiate into mature endosomes or bind with lysosomes – causing 
the contents to endure an acidification process along the way [40]. Caveolin-mediated endocytosis 
involves the assembly of caveolin coats on the cytosolic side of the cellular membrane, resulting 
in the formation of flask-shaped pits approximately 50-100 nm in diameter [37], [41]. The most 
notable use of caveolin-mediated endocytosis by cells is for lipid homeostasis – particularly the 
internalization of cholesterol [41]. One important distinction between clathrin-mediated and 
caveolin-mediated endocytosis is that the caveosomes possess a neutral pH and avoid the 
acidification that the endosomes created by clathrin-mediated endocytosis endure [40]. While 
distinct in their manner of formation, it is known that both clathrin-mediated and caveolin-
mediated endocytosis require complex signaling cascades that have yet to be fully understood  
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[42]. While these two endocytotic pathways are the primary means by which nanoparticles tend to 
be internalized, clathrin- and caveolin-independent endocytosis have also been observed, but the 
mechanisms by which materials are uptaken in these manners remain poorly understood and 
generally described only using negative terms relative to the previously described mechanisms 
[41]. 
Intracellular Trafficking 
Once a nanoparticle or material has been internalized by the cell by some mechanism, it 
must be trafficked to its final destination. Additionally, if the lysosome or the endosome is not the 
final target of the therapeutic, then the nanocarrier must escape from the endosome in order to 
impart the intended effect on the cell. As previously described, the endosomes that encapsulate the 
nanoparticles can have various fates. It is possible that some will be recycled to the plasma 
membrane, thereby releasing the drugs back into the extracellular environment; some will 
differentiate into mature endosomes that fuse with lysosomes containing hydrolytic enzymes that 
degrade the nanoparticles; and some might carry the drugs to the targeted cellular component or 
release the drugs into the cytoplasm due to some functionality inherent to the nanoparticle [43]. 
Due to the variety of mechanisms that can be induced to cause the release of the nanoparticles 
from the endosomes, it is useful to look at a few examples of intracellular trafficking, and how 
designing the nanoparticles appropriately is crucial to their successful use as therapeutic agents.  
Some polyamine-based nanocarrier systems have shown promise for controlled 
intracellular delivery by exploiting the hypothesized “proton sponge” effect. Once internalized by 
an endosome, the carriers become protonated within the acidic environment. As the protons 
accumulate together with their counter ions, an osmotic pressure imbalance is created between the 
endosome and the cytosol. This imbalance stimulates the entrance of water from the cytosol into 
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the endosome, forcing the endosome to swell and ultimately rupture – leading to the distribution 
of the endocytosed nanoparticles into the cytoplasm [44].  
Some therapeutics require delivery to a specific organelle or region within the cell, rather 
than simply being distributed to the cytosol. For instance, some therapeutics target and must be 
delivered to the mitochondria of the cell. Due to the selective and impermeable nature of the 
mitochondrial membrane, a specially designed vector must be used to successful ferry small 
molecule drugs to the organelle [45]. Triphenyl phosphonium (TPP) cation – because of its 
delocalized positive charge and lipophilicity, has proven successful as a carrier for covalently 
conjugated small molecule drugs for this purpose [46].  
Similarly, the design of the nanocarrier must be considered when attempting to target and 
deliver therapeutics to the nucleus. In general, transport across the nuclear envelope occurs in two 
ways: passively, most notably for small ions and macromolecules, and actively, facilitated by the 
binding of oligopeptide sequences to nuclear receptors, known as nuclear localizations signals 
(NLSs) [40]. There has been success in delivering nanoparticles directly to nucleus using 
conjugated NLS based carriers. In fact, NLS-functionalized DOX-loaded PLGA nanoparticles 
were shown to be more successful in delivering drugs to the nucleus of MCF7 cells, relative to 
their non-NLS conjugated particle counterparts [47].  
Though, there are many other strategies for targeting the nucleus of a cell as well – one of 
which is caveolae-mediated nucleus targeting. As previously described, caveolae-mediated 
endocytosis is distinct from clathrin-mediated endocytosis and other endocytic pathways in that 
its caveosomes do not possess an acidic environment, but rather a neutral one – thereby bypassing 
the acidic, as well as enzymatic, degradation of the internalized components. Additionally, the 
cargo of the caveosomes are often directed toward the Golgi Apparatus (GA) or the Endoplasmic 
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Reticulum (ER), which are organelles known to process and redirect cargoes, like proteins and 
macromolecules, from those organelles to other parts of the cell, including the nucleus. Attempts 
have been made to target caveolin-mediated endocytic pathways in order to bring the particles to 
the GA or the ER in the hopes that they will facilitate transport to the nucleus [48]–[50]. In a 
similar vein, attempts have been made to implore saccharide functionalities into polymer 
nanocarriers to mimic the natural process of transporting glycosylated proteins from the ER to the 
nucleus in order to improve delivery [51].  
Passive Targeting 
Designing nanomedicines for targeted intracellular delivery is crucial in order for the 
carried drugs to impart their intended effect on the diseased cell. However, it is equally important 
that the nanoparticles are designed to reach the diseased site in the first place. Regarding drug 
delivery via nanocarriers, there are two types of targeting that must be considered while designing 
the nanoparticles: passive and active. Passive targeting takes advantage of the pathophysiological 
features of the tumor microenvironment in order to facilitate successful accumulation at the 
diseased site, while active targeting generally relies on the binding of a target ligand to a target 
receptor in order to further enhance target specificity and facilitate internalization of the 
nanoparticles. These two strategies of targeting have been illustrated below in Figure 1 [52]. As 
previously described, due to the leaky vasculature and the impaired lymphatic drainage inherent 
to tumors, nanoparticles and macromolecules preferentially accumulate in tumors due to the EPR 
effect. Therefore, what is of the most importance to consider is those characteristics of the 
nanoparticles that allow for the exploitation of this effect and further enhance successful 
accumulation and uptake – namely nanoparticle size, shape, elasticity, and surface chemistry. 
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Figure 1. Schematic representation of both passive and active targeting approaches to enhancing 
the drug delivery capabilities of a nanocarrier.  
 
The size of the nanoparticles affect how they interact with the cell membrane and thus the 
efficiency with which they are uptaken, as well as the mechanism by which they are uptaken. As 
previously mentioned, particles approaching and in the micron size range are internalized by 
micropinocytosis and phagocytosis, and particles in the 50-200 nm range tend to be internalized 
by clathrin- or caveolin-mediated endocytosis. In fact, several studies have determined that, on 
average, the optimized particle size for cellular uptake is approximately 50 nm. Particles of that 
size tend to more efficiently bind with cell membrane receptors and thus facilitate receptor-
mediated endocytosis [53]–[55]. Aside from affecting uptake – its rate and mechanism – size also 
affects the particle’s circulation. As particles surpass a hydrodynamic diameter of approximately 
200 nm, their clearance rate by the reticuloendothelial system increases, thereby reducing the 
carriers’ bioavailability at the target [43], [56].  
19 
Though, size alone does not determine which mechanism is employed for internalization, 
nor does it determine efficiency. In fact, in studying the relationship between nanoparticle size and 
cellular uptake, results from one study are often found to be inconsistent with those of another 
study [43], [57]–[59]. These contradictions are most likely due to the sheer number of factors that 
influence cellular internalization, and the inherent difficulty in unconfounding the effects of each 
factor on uptake. Additionally, there could be unforeseen or undetectable issues that affect 
internalization, such as agglomeration or aggregation. Furthermore, cellular uptake varies between 
cell type. For instance, while embryonic fibroblasts preferentially internalize gold nanoparticles of 
25 nm, rather than larger nanoparticles, epithelial cells preferentially internalized 50 nm gold 
nanoparticles, rather than those larger or smaller [53], [60]. Therefore, when designing a 
nanoparticle to serve as a drug delivery agent, multiple factors must be considered together in order 
to provide a synergistic effect in improving delivery and efficacy.  
As previously mentioned, other factors affect internalization – like shape. However, similar 
to the reports on the effect of size, there is little consensus on the role of shape on internalization. 
In one study performed by Chithrani et al. on the effect of shape on the uptake of gold nanoparticles 
by HeLa cells, the spherical particles were uptaken five times as much as their rod shaped 
counterparts [60]. On the other hand, in one study by Gratton et al. regarding uptake of 
monodisperse hydrogel nanoparticles by HeLa cells, it was found that rod-shaped nanoparticles 
were internalized at much higher rates than the sphere, cylinder, and cube shaped counterparts 
[57]. Additionally, in a study by Xu et al. regarding layered double hydroxide nanoparticles with 
fluorescein isothiocyanate in various morphologies, it was shown that, while the mechanism was 
the same for the various morphologies, the intracellular trafficking was different [61]. Overall, the 
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shape of the nanocarrier must be tailored for the specific class of material, for the target cell type, 
and for the internal destination within the chosen cell.  
Yet another factor inherent to the nanoparticles that can affect uptake is the material’s 
elasticity. The most common parameter used to measure a material’s elasticity – or its stiffness or 
flexibility – is Young’s modulus, wherein a material with a high Young’s modulus is stiff. 
According to a study by Anselmo et al., it was discovered that softer nanoparticles allowed for 
improved circulation times and thus enhanced targeting compared to harder nanoparticles in vivo; 
however, the softer nanoparticles exhibited reduced cellular uptake [62]. In an energetics study of 
cell-nanomaterial interactions using a theoretical model, Yi et al. showed that endocytosis is highly 
dependent on the stiffness of the nanoparticle. Yi et al. explained that softer nanoparticles were 
more difficult to be internalized by a cell due to the larger wetting angle inherent to soft materials 
and the higher extent of spreading by the nanoparticle on the cell membrane. This increased 
spreading creates a large energy barrier to cell membrane wrapping that impedes, and potentially 
even stops, cellular uptake [37], [63]. Therefore, the elasticity of a nanocarrier must be tuned such 
that it is optimized for both ideal circulation and uptake behavior. 
One of the most important characteristics of the nanoparticle is its surface chemistry – its 
charge, hydrophobicity/hydrophilicity, and whether it possesses a stealth coating. The surface 
chemistry affects the nanoparticle-cell membrane interaction and the uptake mechanism, as well 
as the nanoparticle-opsonin interaction during circulation.  According to both in vitro and 
molecular dynamics simulations, both negatively and positively charged particles have better 
adhesion to cell membranes and thus internalization than neutrally charged particles [64], [65]. 
Though, the type of charge affects the membrane of the cells differently. Positively charged 
particles often lead to enhanced fluidity of the cell membrane. On the other hand, negatively 
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charged particles can cause gelation of the cell membrane [66]. Additionally, as charge density 
increases, the energetics of membrane wrapping decrease, improving the ease of internalization. 
However, an increase in charge density can lead to severe disruption of the cell membrane upon 
penetration of the cell by the particles [67]. Therefore, the charge density on a particle needs to be 
optimized for uptake as well as cytotoxicity.  
The hydrophobicity or hydrophilicity of the nanoparticles also affects the interactions of 
the particles with the cell membrane in a similar manner to that of the nanoparticle surface charge. 
Particles that are hydrophobic tend to become embedded in the hydrophobic core of the lipid 
bilayer. On the other hand, particles that are hydrophilic tend to adsorb to the cell membrane 
surface, inducing membrane wrapping. As such, the surface hydrophobicity or hydrophilicity of 
the nanoparticles can induce different response mechanisms by the cells with which they interact 
[68].  
As previously described, it is known that there are advantages to grafting hydrophilic 
stealth coating agents – like poly(ethylene glycol) (PEG) – to the surface of nanoparticles for use 
in biological applications. They shield the cationic particle surface, thereby improving the 
retention of colloidal stability in physiological conditions; they prevent opsonization by serum 
proteins, reducing uptake by macrophages of the mononuclear phagocyte system (MPS); and they 
further enable extravasation by enhancing the circulation time and thus the time to exploit the EPR 
effect. However, the inclusion of a surface graft can also interfere with the ability of the 
nanoparticles to interact with the cell membranes. As previously described, while hydrophobic 
surfaces readily interact with the lipophilic membrane of cells, facilitating cellular uptake, 
hydrophilic surfaces – like those of PEG-conjugated nanoparticles – do not because the required 
membrane wrapping for endocytosis of hydrophilic materials creates an energy barrier that must 
22 
be overcome, thus impeding uptake by cells [69]. Therefore, while designing a nanoparticle with 
ideal properties for passive targeting, the surface chemistry and functionalities must be carefully 
considered – in conjunction with the numerous other factors that affect delivery and uptake.  
Active Targeting 
Passive targeting is crucial for facilitating efficient accumulation of nanoparticles in the 
tumor interstitium and ensuring that the nanoparticle itself does not impede uptake. However, more 
steps need to be taken in order to further promote uptake by the cancer cells. If uptake is not readily 
and sufficiently achieved, it is possible for the drugs to diffuse out of the tumor site, leading to an 
undesirable exposure of the cytotoxic drug to healthy tissues. The promotion of uptake can be 
facilitated by actively targeting the nanoparticles to receptors, proteins, or other components that 
are either unique to cancer cells or overexpressed in them. This active targeting is most often 
achieved by functionalizing the surface of the nanoparticles with a key targeting ligand. Due to the 
uniquely abnormal behavior of cancer, there are numerous different targets that can be considered. 
These targets can be localized in the tumor microenvironment and extracellular matrix, on the 
surface of the cancerous cells, or within the cell. Each environment possesses multiple targets of 
interest. 
In the tumor microenvironment and extracellular matrix, some targets include vascular 
endothelial growth factors (VEGF), vascular cell-adhesion molecules (VCAMs), matrix 
metalloproteinases (MMPs), and integrins – each of which were described or mentioned previously 
in this work. VEGF is highly overexpressed in tumor cells, relative to healthy cells, and it promotes 
tumor angiogenesis and cancer cell proliferation. Additionally, it possesses immunosuppressive 
capabilities – inhibiting the function of T cells, increasing the recruitment of regulatory T cells and 
myeloid-derived suppressor cells, and hindering the differentiation and activation of dendritic 
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cells. As such, VEGF and its receptor, VEGFR, have become key targets for restoring antitumor 
immunity and for impeding the development of tumoral vasculature [68]. Currently, there are 
multiple phase I/II clinical trials using monoclonal antibodies to target VEGF and VEGFR 
pathways [70]. One of these antibodies is Bevacizumab, which binds to VEGF-A and prevents its 
binding with VEGFR1 and VEGFR2 [71]. Additionally, there are numerous tyrosine kinase 
inhibitors which prevent the phosphorylation of VEGFR – thereby blocking the signaling cascades 
that would lead to the stimulation of angiogenesis [72]. Incorporation of these antibodies and 
inhibitors with delivery agents could significantly improve their efficiency, as well as allow for 
the dual delivery of the inhibitor and other chemotherapy drugs to the tumor site – providing a 
synergistic effect for the delivered therapies. 
VCAM-1 is a cell adhesion molecule that was previously known to regulate inflammation-
associated vascular adhesion and the transport of leukocytes like macrophages and T cells. 
However, similar to VEGF, in cancer, increased VCAM-1 expression has been linked to tumoral 
angiogenesis and metastasis [73]. Again, similar to the targeting of VEGF and VEGFR, there have 
been a litany of different peptides and antibodies used in various studies that have been 
functionalized to nanoparticles for the targeting of VCAM-1 for both diagnostic and therapeutic 
purposes. In general, in these approaches, the VCAM-1 is exploited as a marker of the diseased 
site, and the binding of the antibodies or peptides to VCAM-1 facilitate the preferential 
accumulation of the conjugated nanoparticles carrying drugs in the diseased site [74]–[78].  
MMPs are a family of zinc-dependent endopeptidases that are utilized for the remodeling 
of the extracellular matrix. As such, they are often exploited by and overproduced in cancer cells 
in order to cleave necessary cell-adhesion molecules – thereby allowing cell invasion, tumor 
growth, and ultimately metastasis [79]. Several attempts have been made to exploit the presence 
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of these proteinases in tumors. In one study designed, an MMP 2-responsive multifunctional 
liposomal nanocarrier was designed for enhanced tumor targeting. In this case, an MMP-2 
cleavable peptide served as a linker between the liposomal surface and the surface grafted stealth 
agent, PEG, which is known to impede uptake. As such, the cleaving of the peptide linker 
facilitated the cellular uptake of the liposomal nanocarrier carrying cytotoxic drugs that would then 
cause the death of the cancer cell [80]. A similar approach was used in another study, in which the 
MMP substrate peptide was conjugated to the surface of mesoporous silica nanoparticles 
containing cytotoxic drugs. Again, the cleavage of the MMP substrate facilitated cellular uptake 
and ultimately led to cell death – showing the improved target specificity for the MMP-expressing 
tumor site [79], [81].  
Integrins are transmembrane receptors that serve as cell-surface adhesion molecules, and 
they are known for their bidirectional signaling capabilities – integrating processes that occur in 
the intracellular compartment with those of the extracellular environment [82]. As such, integrins 
– through mechanosensing and force-transduction signaling – play a special role in regulating 
important functions like proliferation, gene expression, cell survival,  and cell mobility [83]. 
However, cancer cells often exploit these integrin-mediated processes in order to create an 
environment that promotes cancer progression. In fact, the deregulation of integrin-mediated cell 
adhesion to the extracellular matrix is a crucial step to tumorigenesis – facilitating proliferation, 
invasion, and ultimately metastasis. Therefore, disrupting this exploitation is a key route towards 
treating cancer and preventing its growth [84]. Efforts have been made to target the activity of 
αvβ3 and αvβ5 integrins – key components associated with regulating angiogenesis and tumor 
growth – directly by using the inhibitor, Cilengitide, and they have shown great promise [85]–[88]. 
Though, there are also efforts being made to create integrin-targeted medicines that deliver cargoes 
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such as chemotherapeutics, proapoptotic peptides, and radionucleotides to the tumor cells and the 
surrounding vasculature [86]. For instance, Hood et al. demonstrated the successful delivery of a 
mutant RAF1 gene to a tumor site using an integrin αvβ3-targeted nanoparticle that ultimately 
resulted in the apoptosis of the cancer cells and the regression of the tumor – demonstrating the 
effectiveness of targeted nanoparticles for drug delivery purposes [89]. 
As previously mentioned, there are also many active targeting strategies that involve cell 
surface receptors that are either uniquely expressed or overexpressed in cancer and the use of one 
of a variety of targeting ligands, such as antibodies, proteins, aptamers, peptides, carbohydrates, 
and other small molecules. One of the many receptors that is known to be overexpressed in a 
variety of epithelial cancers is the epidermal growth factor receptor (EGFR) [90]. One of the most 
commonly used targeting ligands for EGFR is Cetuximab, which is a chimeric human-murine 
monoclonal antibody that competitively binds to EGFR [91]. Cetuximab has been used to facilitate 
the targeted delivery of gold nanoparticles to EGFR-positive cancer sites for both therapeutic and 
diagnostic purposes in a multitude of different studies [92]–[97].  
The transferrin receptor is another cell receptor that is often targeted for various cancer 
therapies. While the transferrin receptor is expressed on most normal human tissues, it is expressed 
on malignant cells at levels several fold higher than those of normal cells due to the necessity of 
iron (delivered by the protein, transferrin) for cancer cell proliferation [98]. One method of 
targeting this receptor is through the use of monoclonal antibodies that antagonize the normal 
function of the receptor and induce cytotoxic effects [98]–[102]. Another method of targeting this 
receptor is through the conjugation of transferrin – the targeting moiety and primary receptor 
ligand – directly to the active compound that will facilitate cell death or to a nanocarrier that 
contains the active compound [98]. The targeting of this receptor can prove particularly useful for 
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cancer treatments due to its aforementioned high levels of expression and because of the wealth of 
possibilities of things that can be and have been conjugated to the protein, transferrin, including a 
litany of chemotherapeutics, toxic proteins, peptides, nucleic acids, antibodies, and carriers [98].  
As previously mentioned, aptamers are often used in cell surface targeting strategies for 
drug delivery systems. Aptamers are single-stranded DNA or RNA oligonucleotides that form 
secondary and tertiary structures that can bind to proteins and other cellular targets with high 
specificity, much like antibodies [103]. Aptamers are produced through an iterative in vitro 
selective process called “systemic evolution of ligands by exponential enrichment” (SELEX) 
[104]. During this process, a large random sequence library of ssDNA or ssRNA molecules are 
exposed to the target molecule, with the expectation that a small subset of the aptamers will possess 
the capability to fold in such a way that they may bind to the target molecule with high specificity. 
The non-binding aptamers are then disposed of, and the aptamers that specifically bind to the target 
molecule with high affinity are enriched by a sequential selection round of PCR or RT-PCR 
amplification. This process is iterated – gradually creating aptamer libraries of increasing binding 
affinity – until the best candidate aptamer(s) for the specific target is selected [103], [104]. Due to 
the high binding specificity of the targeting moieties created through this SELEX process, 
aptamers can serve and have served as powerful tools for actively targeting overexpressed 
receptors on cancer cells and facilitating the transport of their conjugated cargoes to diseased sites 
[105]–[110]. 
Certain carbohydrates have also recently received attention for serving as targeting 
moieties for cancer cells – one of which is mannose. The receptor for mannose, MR is often over 
expressed in many tumors because cancer cells exhibit a heightened affinity for carbohydrates, 
relative to that of normal cells, in order to supply the high demand of nutrients necessary for the 
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rapid proliferation of the cancer – making it a reliable target for drug delivery. Additionally, 
although cancer cells exhibit high tendencies to mutate and develop resistance mechanisms, the 
MR has been shown to be a relatively stable marker, making drug delivery to MR over-expressing 
cells more predictable. As such, multiple mannose-functionalized tumor-targeted drug delivery 
systems have been developed and have shown great promise for improving drug efficacy [111]–
[115].  
Yet another molecule considered for targeted delivery strategies is folic acid, which is a 
small molecule vitamin used by eukaryotic cells to synthesize purines and pyrimidines [116]. Its 
uptake is primarily facilitated by a low-affinity-reduced folate carrier. It is also uptaken via the 
high affinity glycosylphosphatidyl-inositol-linked folate receptor (FR), although not to the same 
level as that of the reduced carrier [117], [118]. However, while the carrier only transports reduced 
forms of folic acid, FR is capable of transporting non-physiologic forms of the vitamin into cell, 
as well as folate-conjugated nanoparticles [117]. While only minimally expressed in healthy 
tissues, the FR is over expressed in many tumors due to the need of the cancer cells to supply the 
nutrients necessary for DNA replication and thus cancer proliferation and tumor growth [119], 
[120]. As such, a significant amount of research has been devoted to the creation of folate-
conjugated nanocarriers to facilitate improved target specificity for cancer sites [121]–[128]. 
In the previous section of this work on intracellular trafficking, a few strategies were 
discussed concerning the controlled delivery of cargoes to specific organelles. These strategies can 
be considered methods of active targeting. Though, there are also other ways to actively target 
intracellular components of cancer cells, as there are a multitude of compounds that are 
overexpressed in cancer cells. For instance, cyclooxygenase-2 (COX-2) is one of a family of 
enzymes which catalyze the rate-limiting step in the biosynthesis of prostaglandins, which are 
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proinflammatory lipids. The cyclooxygenase family of enzymes, including COX-2, are located at 
the luminal side of the endoplasmic reticulum and nuclear membrane within the cell [129].  COX-
2, which is the inducible isoform of the enzyme, is known to be upregulated during both 
inflammation and cancer. The induction or overexpression of COX-2 is associated with an 
increased production of PGE2, which is known to modulate cell proliferation, cell death, tumor 
invasion, and angiogenesis. As such, the inhibition and the targeting of COX-2 has received 
attention as a means of treating certain cancers and improving drug delivery overall [129]–[132].  
Chapter Two: Thesis Work 
Stimuli-Responsive Nanoscale Hydrogels for the Improved Delivery of 
Chemotherapeutic Agents 
As indicated by the literature review, due to their versatility and multifunctionality, 
nanoparticles show great promise in improving the efficacy of current therapeutics by overcoming 
the plethora of biological barriers to drug delivery present in the body. In this particular thesis 
work, the nanoparticles of interest are specifically pH-sensitive nanoscale hydrogels. Hydrogels 
are polymeric materials that swell in the presence of water while maintaining a definitive three-
dimensional structure, and they were the first biomaterial to be designed for medical applications 
[133]. As previously described, engineered nanomaterials hold promise for overcoming the various 
limitations to conventional drug delivery for a litany of reasons including but not limited to the 
following: by altering the drug clearance rate and biodistribution, by improving drug solubility, by 
protecting the therapeutics during circulation, and by possessing the ability to deliver multiple 
agents at once to a specific target – thereby providing a synergistic therapeutic effect. However, 
the polymeric nanoparticle subclass of materials is an especially attractive option for cancer 
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therapy for additional reasons. Polymers have a favorable size distribution and a high drug carrying 
capacity. The molecular architecture of the gels can be precise controlled, while possessing a 
variety of chemical structures. The material properties (mechanical, surface, etc.) are tunable, and 
the surface can be easily functionalized with desirable features or moieties. Additionally, 
intelligent polymers that respond to biological cues are of great interest because of their ability to 
provide controlled release at a specific site [6]–[9].  
The nanoparticles studied in this thesis and their delivery capabilities were assessed in the 
context of ovarian cancer. According to current American Cancer Society estimates, over 22,000 
women are diagnosed with ovarian cancer each year, and unfortunately over 14,000 women die 
each year from the disease, making ovarian cancer the 5th leading cause of cancer related deaths 
among women [134].  Because early stage ovarian cancer rarely causes any symptoms, it can often 
be misdiagnosed.  Therefore, it is very difficult to detect, often only observed once it has 
metastasized and entered the late stages of development – making it a particularly dangerous and 
often fatal form of cancer [135].  In fact, while the 5-year survival rate for early stage ovarian 
cancer is about 92%, only about 15% of all cases of the cancer are discovered in this stage, and 
the overall 5-year survival rate for all types of ovarian cancer is only about 47% [134]. Because of 
the severity of the problems associated with ovarian cancer, there is a strong motivation to improve 
upon the current therapies used in its treatment. Additionally, because various ovarian cancer cell 
lines are well-studied and used ubiquitously in cancer studies, it is a good model in which to study 
these nanogel materials and their delivery capabilities.  
Prior Work on Designing Stimuli-Responsive Nanogels 
In Dr. Nicholas Peppas’ biomaterials laboratory, extensive polymerization and materials 
research has already been conducted regarding pH-sensitive hydrogel nanoparticles as delivery 
30 
agents for the chemotherapeutic drug, carboplatin.  Multiple components comprise the nanogels 
and confer different properties necessary for their delivery purposes.  The components include: (i) 
a cationic monomer, 2-(diethylamino) ethyl methacrylate (DEAEMA), which provides the 
nanoparticles with their pH-sensitivity, as well as the characteristic swelling property that allows 
for the drug’s diffusion out of the hydrogels once stimulated; (ii) a hydrophobic monomer, 
cyclohexyl methacrylate (CHMA), which enables tunability of the nanoparticle pKa and is critical 
for the intelligent design of the pH-stimulated swelling response; (iii) a crosslinking agent, 
tetraethylene glycol dimethacrylate (TEGDMA), which gives the nanoparticles their 3-
dimensional properties; and finally, (iv) a surface graft, poly(ethylene glycol) methacrylate 
(PEGMA), which serves as a hydrophilic stealth agent to protect the nanoparticles from 
opsonization during intravenous injection. The tunable pH-sensitivity and swelling properties of 
these nanoparticles has already been assessed in previous studies, showing that the nanogels 
remain collapsed under physiological conditions (pH ~ 7.2-7.4) and swell once internalized by an 
acidifying endosome (pH ~ 6.0-6.5).  
The Problem: Internalization and Target Specificity 
It has yet to be discovered, though, how these nanoparticles are internalized by the ovarian 
cancer cells, and how their composition and surface properties – most notably, those conferred by 
the stealth agent – affect internalization, in terms of uptake mechanism and rate. The efficacy of 
chemotherapeutic drugs depends upon their uptake by the cancer cells.  Barriers to the drugs’ 
internalization will hinder the intended therapeutic effect and could potentially lead to adverse 
symptoms.  Therefore, it is crucial to understand the mechanism by which the nanoscale drug 
delivery agents are internalized and trafficked by the cells in order to more intelligently design the 
composition of the delivery agents for optimized uptake.  
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Furthermore, it has been observed that the vesicles created for different internalization 
mechanisms possess different environmental conditions and trafficking routes. In the cases of both 
clathrin-dependent and clathrin-independent endocytosis, the endosomes possess an acidic pH 
which gradually becomes more acidic as it differentiates into a mature endosome and finally binds 
with a lysosome. In these cases, the pH-responsive nanogels would swell by the “proton-sponge 
effect” and rupture the endosomes, leading to the release of the nanogels’ cargoes into the 
cytoplasm [136]. On the other hand, in the case of caveolin-dependent endocytosis, the endosomes 
created possess a neutral pH. Under these conditions, the nanogels, as they are currently designed, 
would remain collapsed and would fail to deliver the loaded cargoes [40]. Therefore, in order to 
prove that these pH-responsive nanogels possess the potential to serve as effective controlled-
delivery agents, the mechanism by which they are uptaken by cells must be determined. Once the 
mechanism is discovered, the surface properties of the nanoparticles could be tuned through ligand 
functionalization or surface modification for improved target specificity and, thus, drug efficacy.  
If the mechanism of uptake for these nanogels is, in fact, one that will lead to acidification 
within the endosome, the pH-responsive nature of these nanogels will render them suitable for a 
controlled release of the loaded cargo once internalized by a cell, rather than during circulation. 
However, this tunability alone will not necessarily improve the therapeutic effect conferred by 
these nanocarriers. In fact, something must be done in order to make these nanogels target-specific 
for cancer cells, with minimal uptake among healthy tissues.  
As previously described, it is desirable to have nanoparticles that are coated with PEG 
during circulation because the inclusion of a stealth agent will prevent the removal of the 
nanoparticles and their cargoes from the body prematurely. However, it is expected that the 
inclusion of a hydrophilic stealth agent, like PEG, will impede uptake. Therefore, it would prove 
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beneficial to design a nanoparticle that will shed the stealth agent surface graft once in the presence 
of cancerous tissues only. This additional ability to intelligently respond to environmental cues 
will not only improve the target specificity of these nanocarriers for cancer cells but will also 
facilitate improved cellular uptake and thus drug efficacy. 
In order to design such a stimuli-responsive coating, the unique qualities of the tumor 
extracellular environment must be exploited. One potential route for such an exploitation is to 
design an enzyme degradable cross-linker that functionalizes the PEG to the surface of the 
nanogels and that only degrades in the presence of a tumor-specific enzyme or an enzyme that is 
upregulated in cancerous tissues. Cathepsin B is a lysosomal cysteine protease primarily 
responsible for intracellular protein catabolism [137]. However, in a multitude of cancer types, 
including ovarian cancer, Cathepsin B has been shown to contribute to the growth and proliferation 
of tumor cells [138]. While it is confined to lysosomes in healthy tissues, Cathepsin B has been 
shown to be upregulated in cancer and often secreted from the tumor cells through membrane 
vesicle shedding. Upon secretion, the enzyme associates with the cell membrane surface and 
remains within the tumor microenvironment. Cathepsin B then degrades the surrounding 
extracellular matrix components – thereby facilitating tumor invasion and proliferation [139].  
Cathepsin B is known to cleave numerous peptide sequences. Recently, there have been 
studies regarding Cathepsin B-cleavable doxorubicin prodrugs for improved targeted cancer 
therapy. One peptide sequence in particular – the tetrapeptide, Gly-Phe-Leu-Gly (GFLG) – has 
been found to be one of the most suitable cleavable spacers in the doxorubicin-based prodrugs for 
two main reasons: its plasma stability and its rapid hydrolysis in the presence of Cathepsin B. The 
enzyme degradable crosslinker, GLFG, has been used in the creation of numerous doxorubicin-
based prodrugs – one of which, HPMA copolymer-Gly-Phe-Leu-Gly-doxorubicin, is already in 
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phase I/II clinical studies [140]. Therefore, GFLG will prove to be an ideal enzyme degradable 
crosslinker to use in the functionalization of PEG to the current nanogel design in order to assess 
the effect of PEG-shedding on cellular uptake.  
Ultimately, there are three particular aims of this thesis work: (1) to elucidate the 
mechanism by which these nanogels are uptaken by cancer cells, (2) to evaluate how the surface 
properties of these nanogels – i.e. the inclusion of a stealth surface graft, PEG – affect uptake, and 
(3) to evaluate the effect of including a stimuli-responsive coating on cellular uptake. With this 
data, the nanogels can be further optimized in their design and composition for improved target 
specificity and thus drug efficacy.  
Methodology 
Materials 
Poly(ethylene glycol) methyl ether methacrylate (Mn 2080) solution in 50 wt% in water 
(PEGMA), 2-(diethylamino)ethyl methacrylate (DEAEMA), tetraethylene glycol dimethacrylate 
(TEGDMA), cyclohexyl methacrylate (CHMA), myristyltrimethylammonium bromide (MyTAB), 
and the GGGG and GFLG tetrapeptides were purchased from Sigma-Aldrich (Sigma-Aldrich 
Corporation, St Louis, MO). Irgacure 2959 was obtained from Ciba (Ciba Inc., Basel, 
Switzerland). Brij 30 and deuterium oxide (99.8 % D) were purchased from Acros Organics.  
Acetone, 1X Dulbecco’s phosphate buffered saline (DPBS), hydrochloric acid, and sodium 
hydroxide were purchased from Thermo Fisher Scientific (Thermo Fisher Scientific, Waltham, 
MA). OVCAR-3 (ATCC® HTB-161™) and RPMI-1640 Medium (ATCC® 30-2001™) were 
obtained from ATCC (ATCC, Manassas, VA).  Insulin from bovine pancreas solution (10 mg/mL 
insulin in 25 mM HEPES pH 8.2, Catalog I-0516) was obtained from Sigma-Aldrich, and fetal 
bovine serum (Corning, Catalog 35010CV) was obtained from Thermo Fisher Scientific.  Water 
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used in all experiments was deionized (DI) with a Milli-Q Plus Ultrapure Water System (Millipore) 
equipped with a 0.22 μm in-line outlet filter.  All chemicals were used as received. 
Procedure 
These studies determined how the copolymer composition and particle properties played a 
role in cellular internalization.  
First, the internalization mechanism and intracellular distribution of the nanoparticles was 
assessed for previously synthesized nanoparticles of the standard design. Cells used in this study 
were human ovarian carcinoma cells (OVCAR-3 from ATCC) because they have a high genetic 
similarity to ovarian tumors [141]. After passaging the cell line at least three times, numerous sets 
of cells were plated and exposed to different combinations of pharmacological inhibitors. Then, 
after a sufficient incubation period, these cells were exposed to the various types of fluorescently 
labeled nanoparticles, and the internalization was monitored by flow cytometry. 
Second, a series of nanogels with varied composition and properties were synthesized.  All 
nanogels were fluorescently labeled for use in subsequent cell studies.  The formulations were 
varied in the level of PEG coating to determine the influence of the stealth coating on uptake. After 
synthesis and purification, the samples were characterized through a number of analytical methods. 
Nuclear Magnetic Resonance Spectroscopy (NMR) and Fourier-Transformed Infrared 
Spectroscopy (FTIR) were used to confirm that the nanoparticles had been successfully 
synthesized and possessed the desired compositions. Dynamic light scattering (DLS) characterized 
the nanoparticle swelling properties and size, while zeta potential characterized their surface 
properties. Thermogravimetric Analysis (TGA) and Differential Scanning Calorimetry (DSC) 
were used to assess the polymer properties of the nanoparticles. Then, the uptake of the series of 
fluorescently labeled nanogels of varied PEG content was monitored by flow cytometry. 
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Third, two series of nanogels had their surfaces functionalized – one series with the active, 
Cathepsin-cleavable crosslinker Gly-Phe-Leu-Gly (GFLG) and the other series with the non-active 
crosslinker Gly-Gly-Gly-Gly (GGGG). The crosslinkers were attached to PEG (MW:2000) and to 
the nanogel surfaces through an EDC/Sulfo NHS covalent coupling procedure. Samples for each 
nanogel series ranged from 0-20% molar PEG content to further assess the effect of PEG content 
on uptake, as well as the ability of the enzyme to degrade the crosslinker depending on steric 
hindrance. The samples with the inactive peptide crosslinker served as controls for comparison. 
These nanogels, once again, were fluorescently labeled, and uptake was monitored using flow 
cytometry. 
Nanogel Synthesis. Nanogels with varying composition were synthesized using a well-
known oil-in-water emulsion UV-initiated polymerization  [142]. The amount of PEGMA was 
varied from 0 to 18 molar percent.  The comonomer feed was comprised of DEAEMA, CHMA, 
and PEGMA.  Irgacure 2959 was used as a photo-initiator, TEGDMA was used as a crosslinking 
agent, and Brij30 and MYTAB served as emulsifiers.  After reacting for 2.5 hours under UV light, 
unreacted monomers and surfactants were removed by ionomer collapse. After purification, the 
nanogels were fluorescently labeled with Oregon Green 488 carboxylic acid succinimdyl ester 
(OG488). 
Nuclear Magnetic Resonance Spectroscopy (NMR).  Nanogel composition after 
synthesis was confirmed using 1H Proton NMR Spectroscopy.  Nanogels were dissolved in 
deuterated-dimethyl sulfoxide at a concentration of 0.5 mg/mL for testing. 
Fourier Transform Infrared Spectroscopy (FTIR). Nanogel composition after 
synthesis was further confirmed using FTIR. Dry powder samples were produced through 
lyophilization for 48 hours which were then used on the FTIR. Background spectra were 
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collected immediately before each sample and used for background subtraction.  In all cases, 
spectra were averaged over 64 scans with 0.482 cm-1 data spacing. 
Dynamic Light Scattering (DLS) and Zeta Potential. The nanogel particle size, swelling 
response, and surface charge were characterized by DLS and zeta potential.  The particles were 
measured in phosphate buffered saline as a function of pH from 4.0 - 10.0 at a concentration of 0.5 
mg/mL. To characterize the swelling response, the swelling onset and critical pHs were also 
calculated. 
Differential Scanning Calorimetry (DSC). The nanogels were lyophilized for 48 hours 
and then characterized with differential scanning calorimetry (DSC) using a TA Instruments DSC-
Q2000 instrument equipped. Samples were analyzed using Tzero aluminum pans and hermitic lids, 
with an empty pan and lid used as a reference.   To determine thermal transitions, 5 mg of sample 
was transitioned from -70ºC to 350ºC in a heat/cool/heat cycle: (i) first ramping 10ºC per minute 
from 25ºC to 130ºC, (ii) followed by 5ºC per minutes to -70ºC, and (iii) followed by 10ºC per 
minute to 400ºC. 
Thermogravimetric Analysis (TGA). The nanogels were lyophilized for 48 hours and 
then characterized with thermogravimetric analysis (TGA) using a TA Instruments TGA-Q500 
instrument with platinum pans. To determine the decomposition profile, 5 mg of sample was first 
equilibrated to room temperature under nitrogen, subsequently heated 10ºC per minute to 550ºC 
under nitrogen, and followed by an equilibration at 550°C for 5 minutes. 
Nanogel Fluorescent Labeling: Fluorescent labeling of nanoparticles using nanoparticles 
containing primary amines reacted with 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole (NBD chloride) 
in ethanol. NBD chloride reacts with primary amines to form fluorescent NBD-amines. The 
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primary amine, in these cases, was amino ethyl methacrylate (AEMA) which was covalently 
conjugated to the surface of the nanogels during UV polymerization. After reaction of the NBD 
chloride with the nanogels, the unreacted dye was removed from the nanogel samples through 
sequential rounds of dialysis, and then the samples were placed in the dark until use. 
Ovarian Cancer Cell Culture. Cell studies used human ovarian carcinoma, CD44 
overexpressing cells (OVCAR-3 from ATCC) because they have a high genetic similarity to 
ovarian tumors [141].  Cells were maintained using the ATCC protocol with RPMI-1640 medium 
(ATCC) supplemented with 0.01 mg/mL Bovine Insulin and 10% Fetal Bovine Serum. Media was 
changed every two days, and cells were passaged and sub-cultured when they reached 80-90% 
confluency. 
Mechanism of Nanogel Uptake. Several chemicals were added to the cell culture wells in 
order to inhibit specific mechanisms of uptake.  Filipin III was used to inhibit caveolar-dependent 
pathways [58]; Dynasore was used to inhibit clathrin-dependent endocytosis [143]; and 
Chlorpromazine was also used to inhibit clathrin-dependent endocytosis, while having no effect 
on clathrin-independent endocytosis, allowing the removal of the confounding factors associated 
with Dynasore, which, as a dynamin-inhibitor, prevents some clathrin-independent endocytosis, 
as well [58]. Amiloride was used to inhibit macropinocytosis; Wortmannin was used to inhibit 
phagocytosis, as well as macropinocytosis; and finally, one plate of cells was placed in a 4oC 
environment in order to inhibit energy-independent pathways [144], [145].  
EDC/Sulfo NHS Covalent Coupling. PEG(2000)-NHS (pre-activated) was reacted with 
the two tetrapeptides, GGGG and GFLG, at the N-terminals to create PEG-peptide conjugates. 
Each of the PEG-peptide conjugates was reacted at the C-terminal with N-(3-
Dimethylaminopropyl)-N’-ethylcarbodiimide (i.e. EDC) to produce an Acylisourea intermediate, 
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which in the presence of N-Hydroxysuccinimide (NHS) created an amine-reactive Sulfo-NHS 
ester. Finally, these intermediates were reacted with primary amines on the surface of the nanogels 
to create a stable amide bond and thus PEG-peptide-nanogels. The quantity of PEG-peptide reacted 
varied for each sample in order to create a series of nanogels with varied surface conjugations. 0, 
5, 10, 15, and 20 molar % PEG samples were created for both the GGGG and GFLG sample series 
[146].  
Flow Cytometry. Flow cytometry was used to quantify nanoparticle internalization in the 
ovarian cancer cells (OVCAR-3).  Measurements were collected using a BD Accuri Flow 
Cytometer and analyzed using both ForeCyt and FACSDiva software (IntelliCyt, BD 
Biosciences). The results are reported as the average percent of cells (taken over a large number 
of cells, typically 10,000) containing fluorescently-labeled nanoparticles, and all results will be 
reported as the average ± the standard deviation of six independent experiments. 
Results and Discussion 
Aim 1: In accordance with the first aim, the uptake of the standard nanogel design by 
ovarian cancer cells in the presence of various pathway inhibitors was evaluated in order to 
determine the mechanism by which the nanogels are internalized. The cellular uptake data can be 
found in Figure 2. In the presence of Wortmannin and Amiloride, the nanogel internalization was 
not inhibited, suggesting that the cells do not implore macropinocytosis or phagocytosis for the 
nanogel uptake (mechanisms more often reserved for particles in the micron size range). 
Additionally, Filipin III failed to inhibit uptake, and it can thus be concluded that the nanogels are 
not internalized by caveolar-dependent pathways. Nanogel uptake was significantly inhibited by 
incubation of the cells at 4oC, suggesting that at least a portion of the nanogels are internalized by 
an energy-dependent pathway. Though, because uptake was not completely inhibited, the nanogels 
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must be primarily uptaken by an energy-independent pathway. Cellular internalization was much 
more severely inhibited by both Chlorpromazine and Dynasore. Therefore, the OVCAR cells must 
internalize the nanogels by a clathrin-dependent mechanism. As such, the nanogels will be 
enveloped by acidic vesicles that gradually differentiate into mature endosomes. This acidification 
will result in the swelling of gels by the “proton sponge” effect, the rupture of the endosomes, and 
the successful delivery of the nanogel cargo to the cell cytoplasm.   
Aim 2: In the pursuit of the second aim of this thesis work, a series of nanogels were 
synthesized with varied PEG molar content ranging from about 0-18 mol%. Numerous 
characterization and analytical techniques were performed in order to confirm that the particles 
were synthesized as designed and to assess the effect of increasing PEG content on the polymer 
properties. The analytical data can be found in Figure 3 - Figure 7.  
1H NMR and FTIR were used to confirm that the PEG was successfully incorporated into 
the nanoparticles.  By comparing the 1H NMR spectra for the linear polymer and the nanoparticle 
form in Figure 3, it was confirmed that PEG incorporated into the nanoparticles was primarily 
grafted to the surface of the nanoparticles, as intended. Furthermore, the 1H NMR spectra in Figure 
4 exhibits an increasing PEG peak at 3.6 ppm, indicating the successful controlled incorporation 
of PEG. Additionally, the spectra also possess the characteristic nanoparticle peak at 1.3 ppm 
(illustrated in Figure 3, as well). The FTIR data presented in Figure 5 illustrates the increase in 
PEG content for the nanoparticle series by the increasing intensity and definition of the ester C-O-
C stretching peak at 1150 cm-1, the C-H stretching peak at 1350 cm-1, and the C-H bending peak 
at 2900 cm-1.  
TGA, DSC, and zeta potential were used to assess the effect of increasing PEG content on 
the polymer properties of the nanogels. The TGA data presented in Figure 6 showed that the 
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fraction of mass lost between 180 and 285oC decreased as the PEG content of the nanoparticles 
increased. This trend can be attributed with a decrease in the amount of water lost to anhydride 
formation due to the decrease in the quantity of esters present in the samples that contained higher 
PEG content.  The DSC data presented in Figure 6, as well, showed a PEG melting endotherm 
that increased in intensity for samples that contained increasing PEG content. Additionally, as the 
PEG included in the monomer mix prior to polymerization increased, the melting point for the 
synthesized nanoparticles approached that of a PEG homopolymer, 54oC, further substantiating 
controlled incorporation of PEG in the nanoparticles. The zeta potential data for the nanogel series 
can be seen in Figure 7. As the cationic core of the nanogels becomes more shielded with an 
increase in the neutral PEG on the surface of the particles, the surface charge decreases and 
approaches neutrality across the pH range of ~ 3.5-10.5. Additionally, the isoelectric point for all 
nanogels, regardless of ligand density, remained the same. This observation suggests that it is the 
nanogel core composition that determines the isoelectric point, and it further proves that the PEG 
content is segregated to the nanogel surface, as opposed to the internal core polymer network.    
After synthesis and characterization, the nanogels of varied PEG content were 
fluorescently labeled and incubated with ovarian cancer cells (OVCAR-3) for different time 
periods (2, 24, 48, and 72 hours) in order to assess the effect of the nanogel surface properties, as 
well as time, on uptake. The cellular uptake data can be found in Figure 8. As expected, as PEG 
content increased, cellular internalization of the nanogels diminished sharply on all time scales, 
with nearly zero uptake for particles with 10 mol% PEG or greater. As PEG content increases, the 
cationic particle core becomes more shielded, and the surfaces of the nanogels become neutrally 
charged, as well as increasingly hydrophilic – thereby impeding the interaction of the nanogels 
with the cell membranes. As previously described, while the PEGylation of the nanoparticle 
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surface can improve its ability to act as a drug delivery agent by preventing protein adsorption and 
improving circulation as well as extravasation, a significant stealth coating ligand density on the 
nanoparticle surface can also interfere with target cell interactions and thus uptake.  
Aim 3: After evaluating the effect of the nanogel surface properties on uptake, in 
accordance with aim 3, the nanogels with enzyme degradable crosslinkers functionalizing the PEG 
chains to the nanogel surfaces were synthesized and analyzed to ensure successful synthesis. The 
analytical data can be found in  Figure 9 - Figure 16. 
The 1H NMR data presented in Figure 9 illustrates that the PEG-peptide conjugate samples 
contain both the PEG peaks and the respective characteristic peptide peaks, indicating successful 
synthesis of the PEG-peptide intermediates via the carbodiimide coupling reaction. The 1H NMR 
data presented in Figure 10 and Figure 11 similarly contain the necessary PEG, peptide, and 
nanoparticle peaks, proving successful conjugation of the respective PEG-peptide intermediates to 
the nanoparticles. Additionally, the increasing intensity in the PEG peak in both sets of 1H NMR 
data evidences successful controlled grafting of increasing amounts of PEG to the nanoparticle 
surfaces. The FTIR data in Figure 12, similar to that of the previous nanoparticle FTIR spectra, 
shows the increase in PEG content for both series of PEG-peptide-nanoparticle conjugates by the 
increasing intensity and definition of the ester C-O-C stretching peak at 1150 cm-1, the C-H 
stretching peak at 1350 cm-1, and the C-H bending peak at 2900 cm-1. 
TGA and DSC were used to assess the effect of increasing PEG content and the inclusion 
of the peptide linkers on the polymer properties of the nanogels. The TGA data presented in Figure 
13 and Figure 14 showed that the fraction of mass lost between 180 and 285oC decreased as the 
PEG content of the nanogels increased – similar to that of the previous TGA data and for the same 
reason. In comparing the TGA data of the nanogels with and without peptide linkers, it can be seen 
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that the peptide linkers have little to no effect on the polymer properties of the nanogels.  The DSC 
data presented in Figure 13 and Figure 14, as well, showed a PEG melting endotherm that 
increased in intensity for samples that contained increasing PEG content. Additionally, the melting 
point for the PEG-peptide-nanoparticle conjugates approached that of a PEG homopolymer, 54oC, 
similar to that of the previous DSC data, further showing the successful incorporation of PEG and 
the absence of a significant effect of the inclusion of a peptide linker on the overall polymer 
properties. 
DLS was also performed on the PEG-peptide-nanoparticle conjugates and the data 
comparing the size and PDI of the original nanoparticle (before PEG-peptide conjugation) and the 
PEG-peptide-nanoparticle conjugates can be found in Figure 15. There exists a large disparity in 
size between that of the starting nanoparticle and the conjugates, further proving successful 
functionalization of the surface, as the PEG layer thickness contributes to the measured size. 
Additionally, as the PEG content on the nanoparticle surface increases, the measured size of the 
nanoparticles increases. This trend is a result of the PEG chains changing from a “mushroom” 
conformation (coiled and condensed) to a more “dense brush” confirmation (elongated) as the 
ligand density and steric hindrance on the surface increases.  This size data, in conjunction with 
the constant PDI observed, further suggests successful controlled PEG incorporation on 
monodisperse nanoparticles.   
Zeta potential measurements were made for the original nanoparticle (before PEG-peptide 
conjugation) and the PEG-peptide-nanoparticle conjugates in acidic pH, with and without the 
presence of the enzyme, Cathepsin B, and the data can be found in Figure 16. For both sets of 
samples – those with the GGGG and with the GFLG peptide linkers – the PEG-peptide surface 
functionalization shielded the cationic surface of the particle, leading to a decreased effective 
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surface potential, relative to that of the starting nanoparticle. Furthermore, as the surface 
functionalization increased, the shielding increased, leading to the observable downwards trend in 
measured surface potential for both sets of surface modified nanoparticles. Based on the negligent 
change in surface charge for the GGGG peptide crosslinker while in the presence of Cathepsin B, 
it can be concluded that the peptide used is, in fact, non-responsive. On the other hand, for the 
samples with the GFLG peptide crosslinker, while in the presence of Cathepsin B, the surface 
potential returned to that of the original, unshielded nanoparticle – thereby proving that shedding 
occurred and that the GFLG peptide linker is, in fact, responsive and enzyme degradable for each 
ligand density used. 
The surface modified nanoparticles were incubated with ovarian cancer (OVCAR-3) cells 
both with and without the presence of Cathepsin B in order to determine if the use of the enzyme 
degradable crosslinker would facilitate improved uptake. The cellular uptake data can be found in 
Figure 17. It was observed that the non-PEGylated nanoparticles (the starting, control 
nanoparticles) possessed a significant degree of internalization. The PEGylated particles with 
peptide linkers had nearly zero uptake without the presence of the enzyme. However, when the 
enzyme was present, the nanoparticles with the responsive linker had uptake that resembled that 
of the non-PEGylated nanoparticles, while the nanoparticles with the non-responsive linker 
maintained negligible levels of uptake. This data suggests that the cleaving of the responsive linker 
by the enzyme successfully facilitated shedding of the conjugated PEG and thus improved uptake. 
It also further substantiates the previously attained data that suggested that the presence of PEG 
could potentially inhibit uptake – proving the necessity of including a responsive linker in the 
design of this hydrogel-based drug delivery system. 
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Conclusion 
All three aims of this thesis work were achieved. Using the pathway inhibition technique, 
it was determined that the standard P(DEAEMA-co-CHMA)-g-PEGMA based pH-sensitive 
nanoparticle design was internalized by a clathrin-dependent mechanism. As such, upon 
internalization, the nanoparticles will undergo acidification within the endosome as it matures. 
This acidification will cause the swelling of the nanoparticles, due to their pH sensitivity, and the 
endosomes will rupture, releasing the nanoparticles and their cargoes into the cytoplasm as 
intended. By elucidating the mechanism, it has been proven that these nanogels show promise for 
controlled intracellular delivery.  
After determining the mechanism of uptake, the effect of grafting PEG – a known stealth 
coating agent – to the surface of the nanoparticles on cellular uptake was evaluated. It was 
determined that increasing amounts of PEG led to diminished uptake as a result of decreasing 
surface charge and increasing hydrophilicity, both of which impede nanoparticle-cell membrane 
interactions. This data served as the motivation to pursue the third and final aim of this thesis work, 
which was creating a responsive linker that functionalized PEG to the nanoparticle surfaces. The 
responsive linker chosen was the tetrapeptide, Gly-Phe-Leu-Gly, for three main reasons: (1) its 
stability in plasma, (3) its rapid cleavage in the presence of Cathepsin B – an enzyme known to be 
overproduced in cancers and present in the extracellular matrix of tumors, (3) and its previous 
successes in the use of certain prodrug strategies. After synthesizing nanoparticles with PEG 
functionalized to their surfaces by this responsive linker, it was shown that, in the presence of the 
enzyme, the PEG shed from the nanoparticle surfaces and cellular uptake drastically improved. 
Ultimately, a stimuli-responsive nanogel-based drug delivery system was designed with 
multiple functionalities. It can avoid clearance by the MPS during circulation by means of a stealth 
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coating surface graft – improving the loaded drugs half-life; it can then shed that stealth coating 
from the surface when in the presence of cancer cells specifically – thereby facilitating uptake and 
making the drug carrier more target specific; and it can provide controlled intracellular delivery 
by means of its pH-sensitivity. While there is certainly more that can be done to further improve 
upon the current nanogel design, this drug delivery system shows great promise as a platform for 
improving cancer treatments. 
Future Work 
This current nanogel design could be further developed by increasing its target specificity 
for cancerous cells – in this case, ovarian cancer in particular. One way to pursue this increased 
target specificity is to functionalize a ligand to the surface of the nanogels that would preferentially 
bind to a cell membrane receptor that is overproduced in ovarian cancer cells specifically. CD44 
and its variants are transmembrane glycoproteins that serve as cell-adhesion receptors involved in 
multiple cellular processes, such as growth, differentiation, and motility [147]. In normal ovarian 
epithelial cells, though, the expression of CD44 is low, if not all together absent. However, it is 
shown to be expressed in the majority of epithelial ovarian carcinomas [148], [149]. CD44 has 
been shown to bind the hyaluronic acid present in the extracellular matrix of mesothelial cells – 
thereby mediating the adhesion of the ovarian carcinoma cells to the peritoneum and facilitating 
cancer progression and metastasis [149]–[152].  As such, it is possible to functionalize hyaluronic 
acid to the surface of the nanoparticles. Hypothetically, this functionality would lead to the 
preferential binding of the nanoparticles with ovarian cancer cells specifically, thereby facilitating 
and improving their uptake – further enhancing their promise as potent drug delivery systems. 
As seen in this work, significant strides are being made in the field of nanomedicines to 
improve drug efficacy. However, the prospects for their use is actually a rather controversial issue 
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in industry. Some believe that the use of current nanomedicine technologies will not result in an 
improved therapeutic effect due to their low tumor accumulation efficiencies – some being even 
less than 1% [153]. Rather, administered nanoparticles and their cargoes tend to accumulate in 
other sites in the body, like the liver, spleen, and lungs [154]. Furthermore, the sheer number of 
biological barriers to successful drug delivery – as described in this thesis – clearly show the 
difficulties in designing effective nanomedicines. Though, that is not to say that nanomedicines do 
not still possess the potential to serve as effective therapeutics. For instance, it is noteworthy that, 
while the accumulation rates for these nanomedicines at the targeted site are low, they are, 
nevertheless, around 10-100 times more efficient than that of the bare drugs – indicating a clear 
improvement in the potential therapeutic margin of the administered drugs [153]. Therefore, it is 
not necessarily that an alternative to nanomedicines needs to be discovered. Rather, the approach 
to their design needs to be revamped to make their transition to clinical use more rapid and 
efficient; it is crucial that the creators of nanomedicines begin to reassess the scope of the problem.  
One of the potential ways of redefining nanomedicine design is transitioning from a 
formulation-driven approach to a disease-driven development process. This top-to-bottom 
approach is rooted in understanding the biology of the specific target and using that knowledge to 
design a nanomedicine that will exploit the tumor pathophysiology and ensure the right efficacy 
of the drug. Overall, in this approach, there is a more well-defined challenge to overcome which 
will better facilitate the rational design of the nanomedicine. This approach will prove to be more 
successful than attempting to develop a delivery system and then amending it for a specific clinical 
problem, as is often the case in the field currently [155].  Regardless of approach, the design of 
novel targeted delivery systems is an arduous pursuit. However, through a concerted effort by 
scientists across the field of nanomedicine to consider all of the obstacles present in drug delivery, 
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it is certainly possible to innovate new efficacious nanomedicines, as seen in this work – potentially 
improving the quality of life for millions of people.  
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Figures 
 
Figure 2. Ovarian cancer (OVCAR-3) cellular uptake data for the current standard nanogel 
design in the presence of various pathway inhibitors. OVCAR-3 cells were incubated with the 
denoted permutation and concentration of pathway inhibitors for 1 hour prior to a 24-hour 
nanoparticle incubation period. 
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Figure 3. A comparison of the 1H NMR spectra for the linear polymer, P(DEAEMA-co-CHMA)-
g-PEGMA, and the nanoparticle which includes the crosslinker, TEGDMA.  
 
 
Figure 4. 1H NMR of the nanogels synthesized with varied PEG content.  
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Figure 5. FTIR of the nanogels synthesized with varied PEG content.  
 
Figure 6. Thermogravimetric Analysis (TGA-left) and Differential Scanning Calorimetry (DSC-
right) of the nanogels synthesized with varied PEG content.  
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Figure 7. Zeta potential measurement data for the nanogels synthesized with varied PEG content.  
 
 
Figure 8. Ovarian cancer (OVCAR-3) cellular uptake data for the series of nanogels synthesized 
with varied PEG molar content on the surface.  
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Figure 9. 1H NMR for the PEG-GGGG and PEG-GFLG intermediates, as well as PEG2000 for 
comparison.  
 
Figure 10. 1H NMR for the PEG-GFLG-nanoparticle conjugates. 
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Figure 11. 1H NMR for the PEG-GGGG-nanoparticle conjugates. 
 
 
Figure 12. FTIR data for the PEG-GFLG-nanoparticle (top) and PEG-GGGG-nanoparticle 
(bottom) conjugates with varied PEG content. 
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Figure 13. Thermogravimetric Analysis (TGA-left) and Differential Scanning Calorimetry (DSC-
right) data for the PEG-GFLG-nanoparticle conjugates with varied PEG content. 
 
Figure 14. Thermogravimetric Analysis (TGA-left) and Differential Scanning Calorimetry (DSC-
right) data for the PEG-GGGG-nanoparticle conjugates with varied PEG content. 
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Figure 15. DLS data comparing the size and PDI of the original nanoparticle (before PEG-peptide 
conjugation) and the PEG-peptide-nanoparticle conjugates.  
 
Figure 16. Zeta potential data for the original nanoparticle (before PEG-peptide conjugation) and 
the PEG-peptide-nanoparticle conjugates in acidic pH, with and without the presence of the 
enzyme, Cathepsin B.  
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Figure 17. Ovarian cancer (OVCAR-3) cellular uptake data for the original nanoparticle (before 
PEG-peptide conjugation) and the PEG-peptide-nanoparticle conjugates, with and without the 
presence of the enzyme, Cathepsin B.  
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